経鼻ドラッグデリバリーの世界市場-2024年～2031年

レポート概要

経鼻ドラッグデリバリーの世界市場は、2023年の112億米ドルから、2031年には207億米ドルに達し、予測期間2024-2031年のCAGRで8.0%の成長が予測されています。

経鼻ドラッグデリバリーは、鼻腔から薬剤を投与する方法です。この経路では、鼻粘膜の豊富な血管を利用して、消化管や肝臓での初回通過代謝をバイパスして、薬物を血流に直接吸収させることができます。

全身性の薬剤、ワクチン、鼻づまりやアレルギーなどの局所的な症状に対する治療など、さまざまな薬剤を送達するための非侵襲的で便利な選択肢を提供します。吸収と作用の発現が速いため、経鼻ドラッグデリバリーは、片頭痛や痛みなど、迅速な緩和が必要な症状に特に有用です。

市場力学：

促進要因と抑制要因

非侵襲的な薬物投与方法への嗜好の高まり

世界の経鼻ドラッグデリバリー市場は、迅速な作用発現と利便性を提供する非侵襲的方法への嗜好の高まりによって牽引されています。この方法は、緊急時や中枢神経系疾患の治療など、迅速な吸収を必要とする薬剤に特に有益です。経鼻投与による利便性と患者のコンプライアンスの向上も、特に小児や老人といった経口剤や注射剤の使用が困難な人々の間で、その採用を後押ししています。

例えば、2024年7月、テキサス大学メディカルブランチの研究者らは、アルツハイマー病や認知症などの神経変性疾患との闘いにおける重要な進歩を最近発見しました。Science Translational Medicine誌に掲載されたこの研究は、神経変性疾患を有する高齢マウスモデルにおいて、有害なタウ蛋白質の蓄積を除去し、認知機能を改善するという有望な結果を示した革新的な点鼻スプレー治療を紹介しています。

限られた吸収率

世界の経鼻ドラッグデリバリー市場は、鼻粘膜からの局所刺激と吸収の制限による課題に直面しています。薬物によっては、鼻の解剖学的構造および粘膜クリアランス率に起因する不快感や一貫性のない吸収を引き起こす可能性があります。これらの課題は、正確な投与と安定した吸収を必要とする薬剤に対する経鼻ドラッグデリバリーの有効性と受容性を制限しています。

市場セグメンテーション

世界の経鼻ドラッグデリバリー市場は、タイプ、容器タイプ、用途、流通チャネル、地域によって区分されます。

タイプ別では点鼻スプレーが経鼻ドラッグデリバリー市場シェアの約43.3%を占める

タイプ別では、点鼻スプレーが約43.3%を占めました。点鼻スプレーは、経鼻ドラッグデリバリー市場において様々な薬剤を投与するための一般的な方法です。細かい霧状の薬剤を鼻腔内に直接投与するため、血流への吸収が速いです。これは、片頭痛、鼻づまり、アレルギー性鼻炎のような即効性のある薬剤や、オピオイドの過剰摂取のような緊急時に特に有用です。点鼻薬は非侵襲的で使いやすいため、注射や内服薬の代替品として好まれています。

例えば、2023年10月には、風邪やアレルギー性鼻炎、副鼻腔炎による鼻づまりに悩む人々に、より快適で使いやすい鼻腔スプレーを提供する新世代の鼻腔スプレー、オトリビン点鼻ミストが発売されました。消費者健康企業のHaleon社とAptar Pharma社によって開発されたこのイノベーションは、新しい微小液滴技術を使用し、鼻や喉の奥に液だれすることなく、炎症を起こしている部分を均一にカバーする、充実しているが穏やかなミストを吐出します。

市場の地域別シェア

北米は予測期間を通じて市場シェア全体の約38.4%を占めると予測されます。

北米は、認知度の向上と医療施設の改善により、予測期間を通じて市場全体の約38.4%のシェアを占めると推定されます。政府のイニシアチブと有利な償還政策もこの成長に寄与しています。アジアは、大規模な投資、人口の増加、政府の資金援助により、中国とインドを中心に高い成長が見込まれています。

例えば、2024年4月、Amneal Pharmaceuticals社は、FDAの承認後、Over-the-Counter Naloxone Hydrochloride（Naloxone HCI）Nasal Spray, USP, 4mgの発売を発表しました。このジェネリック同等品は米国で製造されており、ヘロイン、フェンタニル、処方オピオイド薬などのオピオイドによる薬物過剰摂取の治療に使用されます。FDAはこの薬を承認しました。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 非侵襲的な薬物投与方法への嗜好の高まり
    • 慢性疾患の増加
  • 抑制要因
    • 吸収率の制限
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 特許分析
• PESTLE分析
• SWOT分析
• DMIオピニオン

第6章 タイプ別

• 点鼻スプレー
• 点鼻薬
• 点鼻ジェル
• 点鼻パウダー

第7章 容器タイプ別

• 加圧容器
• 非加圧容器

第8章 用途別

• アレルギー性鼻炎・非アレルギー性鼻炎
• 鼻づまり
• 副鼻腔炎
• 喘息
• その他

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• AstraZeneca
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Baxter International, Inc
• Becton, Dickinson, and Company
• GlaxoSmithKline PLC
• Johnson & Johnson
• Novartis AG
• Pfizer Inc
• Valeant Pharmaceuticals International, Inc
• Merck & Co., Inc
• Aegis Therapeutics LLC

第13章 付録

Report Overview

Global Intranasal Drug Delivery Market reached US$ 11.2 billion in 2023 and is expected to reach US$ 20.7 billion by 2031, growing at a CAGR of 8.0% during the forecast period 2024-2031.

Intranasal drug delivery is a method of administering medications through the nasal cavity. This route leverages the rich vascularization of the nasal mucosa, allowing drugs to be absorbed directly into the bloodstream, bypassing the gastrointestinal tract and first-pass metabolism in the liver.

It offers a non-invasive and convenient alternative for delivering various medications, including systemic drugs, vaccines, and treatments for local conditions like nasal congestion and allergies. The rapid absorption and onset of action make intranasal drug delivery particularly useful for conditions that require quick relief, such as migraines and pain.

Market Dynamics: Drivers & Restraints

Increasing preference for non-invasive drug administration methods

The global intranasal drug delivery market is driven by the growing preference for non-invasive methods, offering quick onset of action and convenience. This method is particularly beneficial for drugs requiring rapid absorption, such as in emergency settings or treating central nervous system disorders. The convenience and improved patient compliance of intranasal delivery are also boosting its adoption, especially among populations with difficulty with oral or injectable forms, such as pediatric and geriatric patients.

For instance, in July 2024, researchers at the University of Texas Medical Branch recently discovered a significant advancement in the fight against neurodegenerative diseases such as Alzheimer's disease and dementia. The study, published in Science Translational Medicine, introduces an innovative nasal spray treatment that has shown promising results in clearing harmful tau protein build-up and improving cognitive functions in aged mice models with neurodegenerative diseases.

Limited absorption

The global intranasal drug delivery market faces challenges due to local irritation and limited absorption through the nasal mucosa. Certain drugs can cause discomfort and inconsistent absorption due to nasal anatomy and mucociliary clearance rates. These challenges limit the effectiveness and acceptance of intranasal drug delivery for medications requiring precise dosing and consistent absorption.

Market Segment Analysis

The global intranasal drug delivery market is segmented based on type, container type, application, distribution channel, and region.

The nasal spray from the type segment accounted for approximately 43.3% of the intranasal drug delivery market share

The nasal spray from the type segment accounted for approximately 43.3%. Nasal sprays are a popular method for administering various medications in the intranasal drug delivery market. They deliver a fine mist of medication directly into the nasal cavity, allowing rapid absorption into the bloodstream. This is particularly useful for quick-onset drugs like migraines, nasal congestion, and allergic rhinitis, as well as emergencies like opioid overdose. Nasal sprays are non-invasive and easy to use, making them a preferred alternative to injections or oral medications.

For instance, in October 2023, Otrivin Nasal Mist, a new generation of nasal spray, was launched to bring greater comfort and ease of use to people suffering from nasal congestion due to colds, allergic rhinitis, and sinusitis. The innovation, developed by consumer health company Haleon and Aptar Pharma, uses new microdroplet technology to dispense a full but gentle mist that evenly covers inflamed areas, with no dripping at the back of the nose and throat.

Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to increased awareness and improved healthcare facilities. Government initiatives and favorable reimbursement policies are also contributing to this growth. Asia is expected to experience high growth, with China and India dominating due to large investments, a rising population, and government funding.

For instance, in April 2024, Amneal Pharmaceuticals announced the availability of its Over-the-Counter Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, following FDA approval. This generic equivalent is manufactured in the U.S. and is used to treat drug overdose from opioids like heroin, fentanyl, and prescription opioid medications. The FDA has approved the medication.

Market Segmentation

By Type

Nasal Spray

Nasal Drops

Nasal Gel

Nasal Powder

By Container Type

Pressurized Container

Non-pressurized Container

By Application

Allergic and Non-allergic Rhinitis

Nasal Congestion

Sinusitis

Asthma

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include AstraZeneca, Baxter International, Inc., Becton, Dickinson, and Company, GlaxoSmithKline PLC, Johnson & Johnson, Novartis AG, Pfizer Inc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc, Aegis Therapeutics LLC among others.

Key Developments

In November 2023, Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, just announced an expansion of its nasal drug delivery capabilities by adding a family of innovative nasal powder delivery devices developed in partnership with IDC. Intranasal drug delivery is a good alternative to conventional delivery routes for both local and systemic drug delivery due to its simplicity, safety, and faster onset of action.

Why Purchase the Report?

To visualize the global intranasal drug delivery market segmentation based on type, container type, application, distribution channel, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the intranasal drug delivery market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global intranasal drug delivery market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Container Type
• 3.3. Snippet by Application
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing preference for non-invasive drug administration methods
    • 4.1.1.2. Rise in the prevalence of chronic diseases
  • 4.1.2. Restraints
    • 4.1.2.1. Limited absorption
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Patent Analysis
• 5.6. PESTLE Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Nasal Spray*
  • 6.2.1. Introduction
• 6.3. Nasal Drops
• 6.4. Nasal Gel
• 6.5. Nasal Powder

7. By Container Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
• 7.2. Market Attractiveness Index, By Container Type
• 7.3. Pressurized Container*
  • 7.3.1. Introduction
  • 7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.4. Non-pressurized Container

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Allergic and Non-allergic Rhinitis*
  • 8.2.1. Introduction
• 8.3. Nasal Congestion
• 8.4. Sinusitis
• 8.5. Asthma
• 8.6. Others

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. The U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. UK
    • 10.3.7.3. France
    • 10.3.7.4. Italy
    • 10.3.7.5. Spain
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Container Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
• 10.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. AstraZeneca*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Baxter International, Inc
• 12.3. Becton, Dickinson, and Company
• 12.4. GlaxoSmithKline PLC
• 12.5. Johnson & Johnson
• 12.6. Novartis AG
• 12.7. Pfizer Inc
• 12.8. Valeant Pharmaceuticals International, Inc
• 12.9. Merck & Co., Inc
• 12.10. Aegis Therapeutics LLC (*LIST NOT EXHAUSTIVE)

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us